These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 11290888)

  • 21. Thyroid cancer: radiation safety precautions in 131I therapy based on actual biokinetic measurements.
    Liu B; Peng W; Huang R; Tian R; Zeng Y; Kuang A
    Radiology; 2014 Oct; 273(1):211-9. PubMed ID: 24895877
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hemodialysis in patients requiring 131I treatment for thyroid carcinoma.
    Fofi C; Festuccia F; Barberi S; Apponi F; Chiacchiararelli L; Scopinaro F; Punzo G; Menè P
    Int J Artif Organs; 2013 Jun; 36(6):439-43. PubMed ID: 23653300
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Short-term effectiveness of low-dose radioiodune ablative treatment of thyroid remnants after thyroidectomy for differentiated thyroid cancer.
    Vermiglio F; Violi MA; Finocchiaro MD; Baldari S; Castagna MG; Moleti M; Mattina F; Pio Lo Presti V; Bonanno N; Trimarchi F
    Thyroid; 1999 Apr; 9(4):387-91. PubMed ID: 10319946
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized clinical trial comparing 50mCi and 100mCi of iodine-131 for ablation of differentiated thyroid cancers.
    Zaman Mu; Toor R; Kamal S; Maqbool M; Habib S; Niaz K
    J Pak Med Assoc; 2006 Aug; 56(8):353-6. PubMed ID: 16967785
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pulmonary metastases in children and adolescents with well-differentiated thyroid cancer.
    Samuel AM; Rajashekharrao B; Shah DH
    J Nucl Med; 1998 Sep; 39(9):1531-6. PubMed ID: 9744337
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lithium as adjuvant to radioiodine therapy in differentiated thyroid carcinoma: clinical and in vitro studies.
    Liu YY; van der Pluijm G; Karperien M; Stokkel MP; Pereira AM; Morreau J; Kievit J; Romijn JA; Smit JW
    Clin Endocrinol (Oxf); 2006 Jun; 64(6):617-24. PubMed ID: 16712662
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dosimetry in differentiated thyroid carcinoma (12-1402R).
    Minguez P; Genolla J; Celeiro JJ; Fombellida JC
    Med Phys; 2013 Jan; 40(1):012502. PubMed ID: 23298113
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Radioiodine dose for remnant ablation in differentiated thyroid carcinoma: a randomized clinical trial in 509 patients.
    Bal CS; Kumar A; Pant GS
    J Clin Endocrinol Metab; 2004 Apr; 89(4):1666-73. PubMed ID: 15070929
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thyroid remnant ablation in patients with papillary cancer: a comparison of low, moderate, and high activities of radioiodine.
    Kusacic Kuna S; Samardzic T; Tesic V; Medvedec M; Kuna K; Bracic I; Despot M; Dodig D
    Nucl Med Commun; 2009 Apr; 30(4):263-9. PubMed ID: 19247212
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Iodine kinetics and dosimetry in the salivary glands during repeated courses of radioiodine therapy for thyroid cancer.
    Liu B; Huang R; Kuang A; Zhao Z; Zeng Y; Wang J; Tian R
    Med Phys; 2011 Oct; 38(10):5412-9. PubMed ID: 21992360
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The carcinogenic effects of radioiodine therapy for thyroid carcinoma.
    de Vathaire F
    Nat Clin Pract Endocrinol Metab; 2008 Apr; 4(4):180-1. PubMed ID: 18283326
    [No Abstract]   [Full Text] [Related]  

  • 32. Superiority of iodine-123 compared with iodine-131 scanning for thyroid remnants in patients with differentiated thyroid cancer.
    Mandel SJ; Shankar LK; Benard F; Yamamoto A; Alavi A
    Clin Nucl Med; 2001 Jan; 26(1):6-9. PubMed ID: 11139058
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Thyroglobulin flare response after radioiodine ablation in 2 patients with differentiated thyroid cancer.
    Tsang JF; Levin DP; Leslie WD
    Clin Nucl Med; 2015 May; 40(5):421-2. PubMed ID: 25546193
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Radio-iodine therapy in differentiated thyroid cancer: indications and procedures.
    Reiners C; Dietlein M; Luster M
    Best Pract Res Clin Endocrinol Metab; 2008 Dec; 22(6):989-1007. PubMed ID: 19041827
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prospective randomized clinical trial to evaluate the optimal dose of 131 I for remnant ablation in patients with differentiated thyroid carcinoma.
    Bal C; Padhy AK; Jana S; Pant GS; Basu AK
    Cancer; 1996 Jun; 77(12):2574-80. PubMed ID: 8640708
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of dosimetry of radioiodine therapy in benign and malignant thyroid disorders by means of iodine-124 and PET.
    Eschmann SM; Reischl G; Bilger K; Kupferschläger J; Thelen MH; Dohmen BM; Besenfelder H; Bares R
    Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):760-7. PubMed ID: 12029549
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Radioiodine post-surgical remnant ablation in patients with differentiated thyroid cancer: news from the last 10 years.
    Molinaro E; Pieruzzi L; Viola D
    J Endocrinol Invest; 2012; 35(6 Suppl):16-20. PubMed ID: 23014069
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Management of the helpless patient after radioiodine ablation therapy - are we being too strict?
    Williams CE; Woodward AF
    Nucl Med Commun; 2005 Oct; 26(10):925-8. PubMed ID: 16160653
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 131I treatment of thyroid papillary carcinoma in a patient with renal failure.
    Morrish DW; Filipow LJ; McEwan AJ; Schmidt R; Murland KR; von Westarp C; Betcher KB
    Cancer; 1990 Dec; 66(12):2509-13. PubMed ID: 2249192
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A thyroid nodule overtreated twice.
    Yu R
    Endocrinol Diabetes Nutr; 2017; 64(7):396-397. PubMed ID: 28968220
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.